Citizens initiated coverage of Celcuity (CELC) with an Outperform rating and $150 price target The company is focused on targeted therapies in oncology and its gedatolisib regimen “may provide an efficacious option by hitting several targets simultaneously,” the analyst tells investors in a research note. The firm believes the stock has upside based on its positive outlook for the imminent VICTORIA-1 data in the PIK3CA-mutant population and ahead of a likely first approval in July in the PIK3CA wild-type population.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Celcuity’s Earnings Call: Big Data, Bigger Ambitions
- Celcuity Buy Rating Backed by Strong Gedatolisib Data, Upcoming VIKTORIA-1 Catalyst, and Favorable Risk-Reward
- Celcuity price target raised to $141 from $108 at Craig-Hallum
- Celcuity: Clinical Momentum, Strong Balance Sheet, and Regulatory Catalysts Underpin Buy Rating and $122 Target
- Celcuity price target raised to $125 from $115 at Stifel